10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Phenotypic similarity-based approach for variant prioritization for unsolved rare disease: a preliminary methodological report

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Rare diseases (RD) have a prevalence of not more than 1/2000 persons in the European population, and are characterised by the difficulty experienced in obtaining a correct and timely diagnosis. According to Orphanet, 72.5% of RD have a genetic origin although 35% of them do not yet have an identified causative gene. A significant proportion of patients suspected to have a genetic RD receive an inconclusive exome/genome sequencing. Working towards the International Rare Diseases Research Consortium (IRDiRC)’s goal for 2027 to ensure that all people living with a RD receive a diagnosis within one year of coming to medical attention, the Solve-RD project aims to identify the molecular causes underlying undiagnosed RD. As part of this strategy, we developed a phenotypic similarity-based variant prioritization methodology comparing submitted cases with other submitted cases and with known RD in Orphanet. Three complementary approaches based on phenotypic similarity calculations using the Human Phenotype Ontology (HPO), the Orphanet Rare Diseases Ontology (ORDO) and the HPO-ORDO Ontological Module (HOOM) were developed; genomic data reanalysis was performed by the RD-Connect Genome-Phenome Analysis Platform (GPAP). The methodology was tested in 4 exemplary cases discussed with experts from European Reference Networks. Variants of interest (pathogenic or likely pathogenic) were detected in 8.8% of the 725 cases clustered by similarity calculations. Diagnostic hypotheses were validated in 42.1% of them and needed further exploration in another 10.9%. Based on the promising results, we are devising an automated standardized phenotypic-based re-analysis pipeline to be applied to the entire unsolved cases cohort.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

          The American College of Medical Genetics and Genomics (ACMG) previously developed guidance for the interpretation of sequence variants. 1 In the past decade, sequencing technology has evolved rapidly with the advent of high-throughput next generation sequencing. By adopting and leveraging next generation sequencing, clinical laboratories are now performing an ever increasing catalogue of genetic testing spanning genotyping, single genes, gene panels, exomes, genomes, transcriptomes and epigenetic assays for genetic disorders. By virtue of increased complexity, this paradigm shift in genetic testing has been accompanied by new challenges in sequence interpretation. In this context, the ACMG convened a workgroup in 2013 comprised of representatives from the ACMG, the Association for Molecular Pathology (AMP) and the College of American Pathologists (CAP) to revisit and revise the standards and guidelines for the interpretation of sequence variants. The group consisted of clinical laboratory directors and clinicians. This report represents expert opinion of the workgroup with input from ACMG, AMP and CAP stakeholders. These recommendations primarily apply to the breadth of genetic tests used in clinical laboratories including genotyping, single genes, panels, exomes and genomes. This report recommends the use of specific standard terminology: ‘pathogenic’, ‘likely pathogenic’, ‘uncertain significance’, ‘likely benign’, and ‘benign’ to describe variants identified in Mendelian disorders. Moreover, this recommendation describes a process for classification of variants into these five categories based on criteria using typical types of variant evidence (e.g. population data, computational data, functional data, segregation data, etc.). Because of the increased complexity of analysis and interpretation of clinical genetic testing described in this report, the ACMG strongly recommends that clinical molecular genetic testing should be performed in a CLIA-approved laboratory with results interpreted by a board-certified clinical molecular geneticist or molecular genetic pathologist or equivalent.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database

            Rare diseases, an emerging global public health priority, require an evidence-based estimate of the global point prevalence to inform public policy. We used the publicly available epidemiological data in the Orphanet database to calculate such a prevalence estimate. Overall, Orphanet contains information on 6172 unique rare diseases; 71.9% of which are genetic and 69.9% which are exclusively pediatric onset. Global point prevalence was calculated using rare disease prevalence data for predefined geographic regions from the ‘Orphanet Epidemiological file’ (http://www.orphadata.org/cgi-bin/epidemio.html). Of the 5304 diseases defined by point prevalence, 84.5% of those analysed have a point prevalence of <1/1 000 000. However 77.3–80.7% of the population burden of rare diseases is attributable to the 4.2% (n = 149) diseases in the most common prevalence range (1–5 per 10 000). Consequently national definitions of ‘Rare Diseases’ (ranging from prevalence of 5 to 80 per 100 000) represent a variable number of rare disease patients despite sharing the majority of rare disease in their scope. Our analysis yields a conservative, evidence-based estimate for the population prevalence of rare diseases of 3.5–5.9%, which equates to 263–446 million persons affected globally at any point in time. This figure is derived from data from 67.6% of the prevalent rare diseases; using the European definition of 5 per 10 000; and excluding rare cancers, infectious diseases, and poisonings. Future registry research and the implementation of rare disease codification in healthcare systems will further refine the estimates.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Cytoscape.js: a graph theory library for visualisation and analysis

              Summary: Cytoscape.js is an open-source JavaScript-based graph library. Its most common use case is as a visualization software component, so it can be used to render interactive graphs in a web browser. It also can be used in a headless manner, useful for graph operations on a server, such as Node.js. Availability and implementation: Cytoscape.js is implemented in JavaScript. Documentation, downloads and source code are available at http://js.cytoscape.org. Contact: gary.bader@utoronto.ca
                Bookmark

                Author and article information

                Contributors
                david.lagorce@inserm.fr
                Journal
                Eur J Hum Genet
                Eur J Hum Genet
                European Journal of Human Genetics
                Springer International Publishing (Cham )
                1018-4813
                1476-5438
                6 November 2023
                6 November 2023
                February 2024
                : 32
                : 2
                : 182-189
                Affiliations
                [1 ]INSERM, US14 - Orphanet, Plateforme Maladies Rares, ( https://ror.org/02vjkv261) 75014 Paris, France
                [2 ]CNAG-CRG, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, ( https://ror.org/03wyzt892) Baldiri Reixac 4, Barcelona, 08028 Spain
                [3 ]Institute of Medical Genetics and Applied Genomics, University of Tübingen, ( https://ror.org/03a1kwz48) Tübingen, Germany
                [4 ]Centre for Rare Diseases, University of Tübingen, ( https://ror.org/03a1kwz48) Tübingen, Germany
                [5 ]GRID grid.518604.e, Ada Health GmbH, ; Berlin, Germany
                [6 ]GRID grid.249880.f, ISNI 0000 0004 0374 0039, The Jackson Laboratory for Genomic Medicine, ; Farmington, CT 06032 USA
                Author information
                http://orcid.org/0000-0002-7356-7986
                http://orcid.org/0000-0003-4845-5795
                http://orcid.org/0000-0002-0736-9199
                http://orcid.org/0000-0001-9803-7183
                http://orcid.org/0000-0002-2810-3445
                http://orcid.org/0009-0008-3646-7469
                http://orcid.org/0000-0003-4308-6337
                Article
                1486
                10.1038/s41431-023-01486-7
                10853199
                37926714
                16c139f4-fd94-4fd1-a1f1-b0120e7b58b0
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 17 May 2023
                : 13 September 2023
                : 5 October 2023
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100000780, European Commission (EC);
                Award ID: 779257
                Award ID: 779257
                Award ID: 779257
                Award ID: 779257
                Award ID: 779257
                Award ID: 779257
                Award ID: 779257
                Award ID: 779257
                Award ID: 779257
                Award ID: 779257
                Award ID: 779257
                Award ID: 779257
                Award ID: 779257
                Award ID: 779257
                Award Recipient :
                Categories
                Article
                Custom metadata
                © European Society of Human Genetics 2024

                Genetics
                genome informatics,spinocerebellar ataxia
                Genetics
                genome informatics, spinocerebellar ataxia

                Comments

                Comment on this article